RE:Risk for further dilution?PRC is not in the know here about the financials of the Abbvie deal in my opinion. I have thoroughly investigated every angle of that question and to the best of my knowledge there is nothing to indicate a break in disclosure compliance with Abbvie. The shorts simply took advantage of the run, the uncertainty of non disclosure, and diarrhea doubt some here have a fascination with and took it to town, plain and simple.
As for dilution, a more likely scenario is:
1. numbers of Abbvie deal are disclosed per sec reporting compliance
2. Sirona signs a global deal with one to four pet therapy conglomerates
2.5 New CEO is announced
3. Anti-aging trial results in a partnering arrangement with a top 10, likely Abbvie again in my opinion as they already understand in depth the molecular science from skin lightening and the word Botox seems to come up routinely by Sirona, not sure why.
4. New human trials announced for alternative therapy for sglt2
5. The price per share grossly exceeds the minimum threshold requirements for uplisting
6. The company gets a takeout offer and we are all done.
None of these require a significant "heavy lift" here as much of the scientific momentum is there already. Note Anti-vaxxers will not understand that one, ie the scientific facts.
I have been here for 10 yrs too and the odds look reasonable this week as we stand at 0.23, to put it mildly.